Sigma Planning Corp Macrogenics Inc Transaction History

Sigma Planning Corp

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 20, 2022	SELL	$8.12 - $16.9 $189,277 - $393,938	-23,310 Closed	0 $0
Q4 2021 Feb 02, 2022	SELL	$15.91 - $21.88 $238 - $328	-15 Reduced 0.06%	23,310 $374,000
Q3 2021 Oct 28, 2021	SELL	$19.74 - $28.7 $17,272 - $25,112	-875 Reduced 3.62%	23,325 $488,000
Q2 2021 Aug 13, 2021	BUY	$20.49 - $35.63 $300,178 - $521,979	14,650 Added 153.4%	24,200 $650,000
Q1 2021 May 06, 2021	BUY	$18.99 - $33.2 $181,354 - $317,060	9,550 New	9,550 $304,000
Q2 2019 Aug 01, 2019	SELL	$14.51 - $19.71 $153,806 - $208,926	-10,600 Closed	0 $0
Q1 2019 May 01, 2019	BUY	$11.11 - $25.6 $117,766 - $271,360	10,600 New	10,600 $191,000

131

56M

28.3K

197K

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $128M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

Get notified when there are updates to the investment portfolio of Sigma Planning Corp, based on Form 13F filings with the SEC.

Stay updated on Sigma Planning Corp with notifications on news.